Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma; European Myeloma Network. Ozaki S, et al. Among authors: shimizu k. Acta Haematol. 2014;132(2):211-9. doi: 10.1159/000357394. Acta Haematol. 2014. PMID: 24662986 Free article.
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K, Sunami K, Matsumoto M, Maki A, Shimada F, Suzuki K, Shimizu K. Suzuki K, et al. Among authors: shimizu k. Acta Haematol. 2021;144(3):264-274. doi: 10.1159/000508529. Epub 2020 Dec 4. Acta Haematol. 2021. PMID: 33279887 Free PMC article. Clinical Trial.
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Ozaki S, et al. Among authors: shimizu k. J Cancer Res Clin Oncol. 2022 Jan;148(1):191-203. doi: 10.1007/s00432-021-03668-6. Epub 2021 Jun 2. J Cancer Res Clin Oncol. 2022. PMID: 34080068
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: shimizu k. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.
Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).
Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Murakami H, et al. Among authors: shimizu k. Int J Hematol. 2019 Apr;109(4):409-417. doi: 10.1007/s12185-019-02607-z. Epub 2019 Jan 31. Int J Hematol. 2019. PMID: 30701467 Clinical Trial.
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.
Suzuki K, Doki N, Meguro K, Sunami K, Kosugi H, Sasaki O, Takagi T, Murakami H, Shimizu K. Suzuki K, et al. Among authors: shimizu k. Int J Hematol. 2019 Oct;110(4):447-457. doi: 10.1007/s12185-019-02700-3. Epub 2019 Jul 19. Int J Hematol. 2019. PMID: 31325152 Clinical Trial.
7,340 results